Supplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Supplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

<p>Supplementary Table S8. DEGs for 6 months Comparison of CD49d+ and CD49d-</p>

Salvato in:

Dettagli Bibliografici
Autore principale:	Anfal Alsadhan (15907475) (author)
Altri autori:	Jonathan Chen (15907478) (author), Erika M. Gaglione (15032498) (author), Chingiz Underbayev (15907481) (author), Pamela L. Tuma (15907484) (author), Xin Tian (15907487) (author), Lita A. Freeman (15907490) (author), Sivasubramanian Baskar (15907493) (author), Pia Nierman (15907496) (author), Susan Soto (15907499) (author), Andy Itsara (15907502) (author), Inhye E. Ahn (15032501) (author), Clare Sun (14953020) (author), Elena Bibikova (15907505) (author), Tanja Nicole Hartmann (15907508) (author), Maissa Mhibik (15907511) (author), Adrian Wiestner (15907514) (author)
Pubblicazione:	2025
Soggetti:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Immuno-oncology Cell Signaling Cell adhesion Protein tyrosine kinases Drug Resistance Hematological Cancers Leukemias Lymphomas Immunology Immunomodulation
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Supplementary Table S10 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
di: Anfal Alsadhan (15907475)
Pubblicazione: (2025)

Supplementary Table S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
di: Anfal Alsadhan (15907475)
Pubblicazione: (2025)

Supplementary Table S5 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
di: Anfal Alsadhan (15907475)
Pubblicazione: (2025)

Supplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
di: Anfal Alsadhan (15907475)
Pubblicazione: (2025)

Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
di: Anfal Alsadhan (15907475)
Pubblicazione: (2025)

Supplementary Table S9 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
di: Anfal Alsadhan (15907475)
Pubblicazione: (2025)

Table S9 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
di: Zhihang Chen (17315678)
Pubblicazione: (2025)

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC.docx
di: Xinhang Gu (22686224)
Pubblicazione: (2025)

Table S1 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
di: Ruth Flümann (15123900)
Pubblicazione: (2025)

Table S2 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
di: Ruth Flümann (15123900)
Pubblicazione: (2025)

Table S3 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
di: Ruth Flümann (15123900)
Pubblicazione: (2025)

Table S4 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
di: Ruth Flümann (15123900)
Pubblicazione: (2025)

Table S5 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
di: Ruth Flümann (15123900)
Pubblicazione: (2025)

Table S6 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
di: Ruth Flümann (15123900)
Pubblicazione: (2025)

Table S1 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8<sup>+</sup> T Cells
di: Snehanshu Chowdhury (14957031)
Pubblicazione: (2025)

Figure S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
di: Upendra Kumar Soni (15051683)
Pubblicazione: (2025)

Figure S2 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
di: Upendra Kumar Soni (15051683)
Pubblicazione: (2025)

Figure S3 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
di: Upendra Kumar Soni (15051683)
Pubblicazione: (2025)

Figure S4 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
di: Upendra Kumar Soni (15051683)
Pubblicazione: (2025)

Figure S5 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
di: Upendra Kumar Soni (15051683)
Pubblicazione: (2025)

Figure S6 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
di: Upendra Kumar Soni (15051683)
Pubblicazione: (2025)

Supplementary Data File S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
di: Upendra Kumar Soni (15051683)
Pubblicazione: (2025)

Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
di: Ti Wen (15130158)
Pubblicazione: (2025)

Supplementary Table S1 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
di: Nan Ding (15321526)
Pubblicazione: (2025)

Supplementary Table S2 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
di: Nan Ding (15321526)
Pubblicazione: (2025)

Filamin A KO and S2152A KI reduce KSHV de novo infection of cell-free virions.
di: Xiaojuan Li (351842)
Pubblicazione: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
di: Erika Y. Faraoni (14844897)
Pubblicazione: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
di: Erika Y. Faraoni (14844897)
Pubblicazione: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
di: Erika Y. Faraoni (14844897)
Pubblicazione: (2025)

Supplementary Tables from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
di: Francesco Maura (15022226)
Pubblicazione: (2025)

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
di: Ernesto Gargiulo (15134961)
Pubblicazione: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
di: Ernesto Gargiulo (15134961)
Pubblicazione: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
di: Ernesto Gargiulo (15134961)
Pubblicazione: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
di: Ernesto Gargiulo (15134961)
Pubblicazione: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
di: Ernesto Gargiulo (15134961)
Pubblicazione: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
di: Ernesto Gargiulo (15134961)
Pubblicazione: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
di: Ernesto Gargiulo (15134961)
Pubblicazione: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
di: Jonathan M.J. Derry (16648337)
Pubblicazione: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
di: Jonathan M.J. Derry (16648337)
Pubblicazione: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
di: Jonathan M.J. Derry (16648337)
Pubblicazione: (2025)

Cannot write session to /tmp/vufind_sessions/sess_spq6i4m6s3nfbb5opvq462bi9m